Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sorafenib regulates c-CBL gene-mediated chemoresistance in acute myeloid leukemia cells.

Hematology (Amsterdam, Netherlands) - 1 Dec 2023

Sun Qixin, Wu Bingyi, Meng Fanyi, Yao Qianqian, Huang Zhiwei, Xu Jianhui, Zhu Zhigang

Abstract excerpt

Chemotherapeutic regimens containing sorafenib are widely used in salvage treatment for patients with relapsed and refractory acute leukemia, especially those with FLT3-ITD mutations. However, the therapeutic effects in individuals are heterogeneous, and the effective maintenance period is relatively short. Our clinical analysis showed patients with high c-kit (CD117) expression in leukemia cells generally had a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Proto-Oncogene Proteins c-cbl

Share to Receptor Protein-Tyrosine Kinases

Share to Sorafenib

Source

Identifiers

PMID: 37199372
DOI: 10.1080/16078454.2023.2204620

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib regulates c-CBL gene-mediated chemoresistance in acute myeloid leukemia cells.PMID 37199372Read ↗

The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategiesSemantic proximity Read ↗

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemiaSemantic proximity Read ↗

Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.Semantic proximity Read ↗

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disordersSemantic proximity Read ↗

Role of CBL Mutations in Cancer and Non-Malignant PhenotypeSemantic proximity Read ↗

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.Semantic proximity Read ↗

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.Semantic proximity Read ↗

The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related DiseasesSemantic proximity Read ↗

CASK Silence Enhances Chemosensitivity of Hepatocellular Carcinoma Through activating Apoptosis, Inducing JNK/c-Jun-Mediated Autophagic Cell Death and Decreasing ABCG2Semantic proximity Read ↗

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.Semantic proximity Read ↗

Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocellular carcinoma through ubiquitin-mediated degradation of SLTM and subsequent Notch pathway activationSemantic proximity Read ↗

Cbl and Human Myeloid Neoplasms: The Cbl Oncogene Comes of AgeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.